Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Combination therapy for 9+ months maintains symptom improvements after stopping alpha-blockers or finasteride.

Aumolertinib effectively controls lung cancer and improves quality of life.

Non-Kuwaiti COVID-19 patients had worse health outcomes than Kuwaitis, likely due to poorer socioeconomic conditions.

Cancer patients with COVID-19 face higher risks due to possible additional infections.

Patients with advanced breast cancer and high hormone receptor levels who had surgery for ovarian/pelvic metastases lived longer, especially if they had high estrogen receptor levels.

Combination therapy is better for long-term control and outcomes in type 2 diabetes.

The document suggests that clinical trials for PCOS should focus on meaningful primary outcomes like live birth rates, rather than less reliable surrogate markers.

Asian patients with Frontal Fibrosing Alopecia often lose eyebrow hair and respond well to combined antiandrogen or antimalarial and topical treatments.

Deucravacitinib improves symptoms and reduces inflammation in Lichen Planopilaris.

Finasteride effectively reduces hair growth in women with idiopathic hirsutism, but requires careful contraception during treatment.

Nutritional education reduces chemotherapy side effects and improves health in breast cancer patients.

Personalized thiopurine dosing based on NUDT15 genotyping can improve long-term outcomes for ulcerative colitis and Crohn's disease patients.

Ginger extract helps hair growth and reduces the need for prednisolone in alopecia areata patients.

Baricitinib is an effective treatment for severe alopecia areata.

Men with advanced liver disease and high oestrone and low testosterone levels have worse health outcomes.

Most patients with rheumatoid arthritis continued methotrexate treatment over two years, but those who stopped and restarted experienced more side effects and less improvement.

Canakinumab's effect on COVID-19 outcomes is unclear.

Researchers created a new tool to measure the effects of alopecia areata from the patient's view, focusing on hair loss, daily life, and emotional health.

High-quality validation studies are needed to improve alopecia areata patient-reported outcome measures.

Topical finasteride/minoxidil is effective but not better than oral finasteride for hair loss.

Hair regrowth in Alopecia Areata patients leads to increased satisfaction and reduced stress.

Most men using teledermatology for hair loss treatment saw improved hair and self-esteem, with some experiencing side effects.

Men face more severe COVID-19 outcomes, while women are more likely to have long-term symptoms.

Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.

Activated PRP effectively increases hair density and reduces hair loss in alopecia.

The Blood Glucose Management Service improved patient safety and outcomes in managing blood sugar in hospitalized patients.

Patient-reported hair improvements align with actual hair density changes, not hair width.

The document suggests a need for collaboration, better evidence, and a responsible framework to safely and effectively advance regenerative therapies to clinical use.

GT20029 showed some hair growth improvement, but longer studies are needed for better results.